Shopping Cart
- Remove All
- Your shopping cart is currently empty
RGH-5526 is a novel antihypertensive drug. It causes an increase in hypothalamic norepinephrine (NA) turnover (utilization), and the increase in hypothalamic noradrenergic neuron activity may lead to a decrease in peripheral sympathetic nerve activity, resulting in a significant reduction in blood pressure.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | 1.444 € | 6-8 weeks | |
50 mg | 1.881 € | 6-8 weeks | |
100 mg | 2.375 € | 6-8 weeks |
Description | RGH-5526 is a novel antihypertensive drug. It causes an increase in hypothalamic norepinephrine (NA) turnover (utilization), and the increase in hypothalamic noradrenergic neuron activity may lead to a decrease in peripheral sympathetic nerve activity, resulting in a significant reduction in blood pressure. |
In vivo | Following prolonged treatment, RGH-5526 does not influence the hypothalamic monoamine oxidase (MAO)-activity. Results show a sharp (61%) decrease the hypothalamic Noradrenaline (NA) level 2 h after the administration of 10 mg/kg of RGH-5526, and this effect lasts for 4 to 6 h. It is shown that RGH-5526 exerts a greater NA lowering effect in the hypothalamus than in the periphery[1]. |
Alias | GYKI-11679 |
Molecular Weight | 335.4 |
Formula | C16H25N5O3 |
Cas No. | 69579-13-1 |
Relative Density. | 1.22g/cm3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.